M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259–2267 (2023). Article CAS PubMed PubMed Central Google Scholar Taubmann, J. et al. Chimeric antigen receptor T cell treatment: unraveling the role of B cells in...
OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ...
Bispecific T-cell engagerAntibody-drug conjugateMultiple myeloma (MM) remains an incurable disease with the majority of patients experiencing disease relapse despite response to initial therapy. Antibody-drug conjugates (ADCs) and bispecific T-cell engagers are innovative immunotherapeutic approaches currently...
Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and Bヽell non〩odgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and smallヽell lung cancer). BiTE molecules with an extended half﹍ife...
Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation Nat Cancer, 4 (11) (2023), pp. 1536-1543 CrossrefView in ScopusGoogle Scholar 15 S Mailankody, SM Devlin, J Landa, et al. GPRC5D-targeted CAR T cells fo...
B-cell maturation antigen (BCMA) essential for the long-term survival of plasma cells is highly expressed on the malignant plasma cells in multiple myeloma (MM) with almost no expression on normal cells, which can be the promising target for T-cell based immunotherapy [57]. A first-in-huma...
Teclistamab-cqyv (Tecvayli) was approved in 2022 as the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager to be indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including...
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cell
摘要: A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivoLeukemia advance online publication, January 13 2017. doi:1 ...DOI: 10.1038/leu.2016.388 被引量: 6
Tapia-Galisteo, A. et al. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.Oncoimmunology11, 2034355 (2022). ArticlePubMedPubMed CentralGoogle Scholar Zuch de Zafra, C. L. et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recrui...